OSAM
NGNE icon

O'Shaughnessy Asset Management’s Neurogene NGNE Stock Holding History

O'Shaughnessy Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1
Closed – – 2172
2020
Q3 		$0 Hold
1
– – ﹤0.01% 1955
2020
Q2 		$0 Buy
+1
New +$261 ﹤0.01% 1834

Other funds holding NGNE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

O'Shaughnessy Asset Management's NGNE Position: Q4 2020 in Review

O'Shaughnessy Asset Management sold out of Neurogene (NGNE) in Q4 2020, closing a stake of 1 share.

O'Shaughnessy Asset Management first reported a position in NGNE in Q2 2020 and held it in 2 quarters. The position peaked at $0 in Q3 2020. 84 funds tracked by Wall St. Rank hold NGNE as of Q4 2020.

  • O'Shaughnessy Asset Management reported no remaining Neurogene position as of Q4 2020 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 1 Neurogene share in Q4 2020.
  • O'Shaughnessy Asset Management first reported a position in Neurogene in Q2 2020 and held it in 2 quarters.
  • O'Shaughnessy Asset Management's Neurogene position peaked at $0 in Q3 2020.
  • 84 funds tracked by Wall St. Rank held Neurogene as of Q4 2020.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.